Cytoprotective-selective activated protein C therapy for ischaemic stroke

Thrombosis and Haemostasis

Volumn 112, Issue 5, 2014, Pages 883-892

  Mosnier, Laurent O ^a   Zlokovic, Berislav V ^b   Griffin, John H ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Activated protein C; EPCR; PAR1; PAR3; Stroke

Indexed keywords

ACTIVATED PROTEIN C; APOLIPOPROTEIN E; BLOOD CLOTTING FACTOR; ENDOTHELIAL PROTEIN C RECEPTOR; GLYCOPROTEIN IB; METALLOPROTEINASE; N METHYL DEXTRO ASPARTIC ACID; PLASMA PROTEIN; PLASMINOGEN ACTIVATOR; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 3; SPHINGOSINE 1 PHOSPHATE RECEPTOR; THROMBIN; 3K3A-APC PROTEIN; CELL SURFACE RECEPTOR; LEUKOCYTE ANTIGEN; NEUROPROTECTIVE AGENT; PROCR PROTEIN, HUMAN; PROTEIN C; PROTEINASE ACTIVATED RECEPTOR; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

ANTICOAGULATION; ARTICLE; BRAIN ISCHEMIA; CELL PROTECTION; CLINICAL TRIAL (TOPIC); FIBRINOLYTIC THERAPY; HUMAN; PROTEIN ANALYSIS; QUALITY OF LIFE; QUANTITATIVE ASSAY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; ANIMAL; BIOLOGICAL MODEL; BLOOD CLOTTING; C57BL MOUSE; CHEMICAL STRUCTURE; DRUG EFFECTS; DRUG SCREENING; ENZYME ACTIVATION; HEMORRHAGE; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN CONFORMATION; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIGENS, CD; BLOOD COAGULATION; BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; HEMORRHAGE; HUMANS; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; MODELS, MOLECULAR; NEUROPROTECTIVE AGENTS; PROTEIN C; PROTEIN CONFORMATION; RECEPTORS, CELL SURFACE; RECEPTORS, PROTEINASE-ACTIVATED; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84908507268     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-05-0448     Document Type: Article

References (90)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095–2128.
2. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2014 update: a report from the american heart association. Circulation 2014; 129: e28-e292.
3. Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2010. National Vital Statistics Reports 2013; 61: 1–118.
4. Thrift AG, Cadilhac DA, Thayabaranathan T, et al. Global stroke statistics. Int J Stroke 2014; 9: 6–18.
5. Luengo-Fernandez R, Gray AM, Bull L, et al. Quality of life after TIA and stroke: ten-year results of the Oxford Vascular Study. Neurology 2013; 81: 1588–1595.
6. Grossman AW, Broderick JP. Advances and challenges in treatment and prevention of ischaemic stroke. Ann Neurol 2013; 74: 363–372.
7. Bivard A, Lin L, Parsonsb MW. Review of Stroke Thrombolytics. J Stroke 2013; 15: 90–98.
8. Lees KR, Bluhmki E, von KR, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695–1703.
9. The NINDS t-PA Stroke Study Group. Intracerebral haemorrhage after intravenous t-PA therapy for ischaemic stroke. Stroke 1997; 28: 2109–2118.
10. Lackland DT, Roccella EJ, Deutsch AF, et al. Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. Stroke 2014; 45: 315–353.
11. Mazighi M, Chaudhry SA, Ribo M, et al. Impact of onset-to-reperfusion time on stroke mortality: a collaborative pooled analysis. Circulation 2013; 127: 1980–1985.
12. Manning NW, Campbell BC, Oxley TJ, et al. Acute ischaemic stroke: time, penumbra, and reperfusion. Stroke 2014; 45: 640–644.
13. Tymianski M. Novel approaches to neuroprotection trials in acute ischaemic stroke. Stroke 2013; 44: 2942–2950.
14. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109: 3161–3172.
15. Castellino FJ, Ploplis VA. The protein C pathway and pathologic processes. J Thromb Haemost 2009; 7 (Suppl 1): 140–145.
16. Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 2006; 32: 49–60.
17. Bouwens EA, Stavenuiter F, Mosnier LO. Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway. J Thromb Haemost 2013; 11: 242–253.
18. Rezaie AR. The occupancy of endothelial protein C receptor by its ligand modulates the PAR-1 dependent signalling specificity of coagulation proteases. IUBMB Life 2011; 63: 390–396.
19. Russo A, Soh UJ, Trejo J. Proteases Display Biased Agonism at Protease-Activated Receptors: Location matters! Mol Interv 2009; 9: 87–96.
20. Weiler H. Multiple receptor-mediated functions of activated protein C. Hamostaseologie 2011; 31: 185–195.
21. Knoebl PN. Severe congenital protein C deficiency: the use of protein C concentrates (human) as replacement therapy for life-threatening blood-clotting complications. Biologics 2008; 2: 285–296.
22. Jalbert LR, Rosen ED, Moons L, et al. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice. J Clin Invest 1998; 102: 1481–1488.
23. Ishiguro K, Kojima T, Kadomatsu K, et al. Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest 2000; 106: 873–878.
24. Cui J, Eitzman DT, Westrick RJ, et al. Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood 2000; 96: 4222–4226.
25. Macko RF, Killewich LA, Fernández JA, et al. Brain-specific protein C activation during carotid artery occlusion in humans. Stroke 1999; 30: 542–545.
26. Macko RF, Ameriso SF, Gruber A, et al. Impairments of the protein C system and fibrinolysis in infection-associated stroke. Stroke 1996; 27: 2005–2011.
27. Wang L, Tran ND, Kittaka M, et al. Thrombomodulin expression in bovine brain capillaries. Anticoagulant function of the blood-brain barrier, regional differences, and regulatory mechanisms. Arterioscler Thromb Vasc Biol 1997; 17: 3139–3146.
28. Malek AM, Jackman RW, Rosenberg RD, et al. Endothelial expression of thrombomodulin is reversibly regulated by fluid shear stress. Circ Res 1994; 74: 852–860.
29. Folsom AR, Ohira T, Yamagishi K, et al. Low protein C and incidence of ischaemic stroke and coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. J Thromb Haemost 2009; 7: 1774–1778.
30. Zlokovic BV, Griffin JH. Cytoprotective protein C pathways and implications for stroke and neurological disorders. Trends Neurosci 2011; 34: 198–209.
31. Danese S, Vetrano S, Zhang L, et al. The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood 2010; 115: 1121–1130.
32. Bock F, Shahzad K, Vergnolle N, et al. Activated protein C based therapeutic strategies in chronic diseases. Thromb Haemost 2014; 111: 610–617.
33. Shibata M, Kumar SR, Amar A, et al. Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischaemic stroke. Circulation 2001; 103: 1799–1805.
34. Cheng T, Liu D, Griffin JH, et al. Activated protein C blocks p53-mediated apoptosis in ischaemic human brain endothelium and is neuroprotective. Nat Med 2003; 9: 338–342.
35. Griffin JH, Zlokovic BV, Fernández JA. Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke. Semin Hematol 2002; 39: 197–205.
36. Guo H, Liu D, Gelbard H, et al. Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron 2004; 41: 563–572.
37. Liu D, Cheng T, Guo H, et al. Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med 2004; 10: 1379–1383.
38. Cheng T, Petraglia AL, Li Z, et al. Activated protein C inhibits tissue plasminogen activator-induced brain haemorrhage. Nat Med 2006; 12: 1278–1285.
39. Zlokovic BV, Zhang C, Liu D, et al. Functional recovery after embolic stroke in rodents by activated protein C. Ann Neurol 2005; 58: 474–477.
40. Wildhagen KC, Lutgens E, Loubele ST, et al. The structure-function relationship of activated protein C. Lessons from natural and engineered mutations. Thromb Haemost 2011; 106: 1034–1045.
41. Rezaie AR. Regulation of the protein C anticoagulant and antiinflammatory pathways. Curr Med Chem 2010; 17: 2059–2069.
42. Bae JS, Yang L, Manithody C, et al. Engineering a disulfide bond to stabilize the calcium binding loop of activated protein C eliminates its anticoagulant but not protective signalling properties. J Biol Chem 2007; 282: 9251–9259.
43. Han MH, Hwang SI, Roy DB, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008; 451: 1076–1081.
44. Mosnier LO, Gale AJ, Yegneswaran S, et al. Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood 2004; 104: 1740–1745.
45. Mosnier LO, Yang XV, Griffin JH. Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. J Biol Chem 2007; 282: 33022–33033.
46. Gupta A, Gerlitz B, Richardson MA, et al. Distinct Functions of Activated Protein C Differentially Attenuate Acute Kidney Injury. J Am Soc Nephrol 2009; 20: 267–277.
47. Harmon S, Preston RJ, Ainle FN, et al. Dissociation of activated protein C functions by elimination of protein S cofactor enhancement. J Biol Chem 2008; 283: 30531–30539.
48. Ni Ainle F, O’Donnell JS, Johnson JA, et al. Activated protein C N-linked glycans modulate cytoprotective signalling function on endothelial cells. J Biol Chem 2011; 286: 1323–1330.
49. Preston RJ, Ajzner E, Razzari C, et al. Multifunctional specificity of the protein C/activated protein C GLA domain. J Biol Chem 2006; 281: 28850–28857.
50. Yang L, Bae JS, Manithody C, et al. Identification of a specific exosite on activated protein C for interaction with protease activated receptor 1. J Biol Chem 2007; 282: 25493–25500.
51. Mosnier LO, Zampolli A, Kerschen EJ, et al. Hyper-antithrombotic, non-cytoprotective Glu149Ala-activated protein C mutant. Blood 2009; 113: 5970–5978.
52. Guo H, Wang Y, Singh I, et al. Species-dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity. J Neurochem 2009; 109: 116–124.
53. Kerschen EJ, Fernandez JA, Cooley BC, et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med 2007; 204: 2439–2448.
54. Wang Y, Sinha RK, Mosnier LO, et al. Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischaemic stroke in mice. Blood Cells Mol Dis 2013; 51: 104–108.
55. Walker CT, Marky AH, Petraglia AL, et al. Activated protein C analog with reduced anti-coagulant activity improves functional recovery and reduces bleeding risk following controlled cortical impact. Brain Res 2010; 1347: 125–131.
56. Guo H, Singh I, Wang Y, et al. Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity. Eur J Neurosci 2009; 29: 1119–1130.
57. Wang Y, Thiyagarajan M, Chow N, et al. Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity. Stroke 2008; 40: 1864–1869.
58. Wang Y, Zhao Z, Chow N, et al. Activated protein C analog protects from ischaemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats. Stroke 2013; 44: 3529–3536.
59. Wang Y, Zhang Z, Chow N, et al. An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischaemic stroke in rodents. Stroke 2012; 43: 2444–2449.
60. Bir N, Lafargue M, Howard M, et al. Cytoprotective-selective activated protein C attenuates Pseudomonas aeruginosa-induced lung injury in mice. Am J Respir Cell Mol Biol 2011; 45: 632–641.
61. Chen B, Friedman B, Whitney MA, et al. Thrombin activity associated with neuronal damage during acute focal ischaemia. J Neurosci 2012; 32: 7622–7631.
62. Chen B, Cheng Q, Yang K, et al. Thrombin mediates severe neurovascular injury during ischaemia. Stroke 2010; 41: 2348–2352.
63. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3: 1800–1814.
64. Mosnier LO, Sinha RK, Burnier L, et al. Biased agonism of protease-activated receptor 1 by activated protein C caused by non-canonical cleavage at Arg46. Blood 2012; 120: 5237–5246.
65. Soh UJ, Trejo J. Activated protein C promotes protease-activated receptor-1 cytoprotective signalling through beta-arrestin and dishevelled-2 scaffolds. Proc Natl Acad Sci USA 2011; 108: E1372-E1380.
66. Canto I, Soh UJ, Canto I, et al. Allosteric modulation of protease-activated receptor signalling. Mini Rev Med Chem 2012; 12: 804–811.
67. Reiter E, Ahn S, Shukla AK, et al. Molecular mechanism of ββ-Arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol 2012; 52: 179–197.
68. Wisler JW, Xiao K, Thomsen AR, et al. Recent developments in biased agonism. Curr Opin Cell Biol 2014; 27C: 18–24.
69. McLaughlin JN, Patterson MM, Malik AB. Protease-activated receptor-3 (PAR3) regulates PAR1 signalling by receptor dimerisation. Proc Natl Acad Sci USA 2007; 104: 5662–5667.
70. Burnier L, Mosnier LO. Novel mechanisms for activated protein C cytoprotective activities involving non-canonical activation of protease-activated receptor 3. Blood 2013; 122: 807–816.
71. Madhusudhan T, Wang H, Straub BK, et al. Cytoprotective signalling by activated protein C requires protease activated receptor-3 in podocytes. Blood 2012; 119: 874–883.
72. Bae JS, Rezaie AR. Protease activated receptor 1 (PAR-1) activation by thrombin is protective in human pulmonary artery endothelial cells if endothelial protein C receptor is occupied by its natural ligand. Thromb Haemost 2008; 100: 101–109.
73. Deane R, LaRue B, Sagare AP, et al. Endothelial protein C receptor-assisted transport of activated protein C across the mouse blood-brain barrier. J Cereb Blood Flow Metab 2009; 29: 25–33.
74. Zhong Z, Ilieva H, Hallagan L, et al. Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest 2009; 119: 3437–3449.
75. Abu FR, Nassar T, Yarovoi S, et al. Blood-brain barrier permeability and tPAmediated neurotoxicity. Neuropharmacology 2010; 58: 972–980.
76. Jin R, Yang G, Li G. Molecular insights and therapeutic targets for blood-brain barrier disruption in ischaemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis 2010; 38: 376–385.
77. Gorbacheva LR, Storozhevykh TP, Pinelis VG, et al. Activated protein C via PAR1 receptor regulates survival of neurons under conditions of glutamate excitotoxicity. Biochemistry 2008; 73: 717–724.
78. Gorbacheva L, Pinelis V, Ishiwata S, et al. Activated protein C prevents glutamate- and thrombin-induced activation of nuclear factor-kappaB in cultured hippocampal neurons. Neuroscience 2010; 165: 1138–1146.
79. Thiyagarajan M, Fernandez JA, Lane SM, et al. Activated protein C promotes neovascularisation and neurogenesis in postischaemic brain via protease-activated receptor 1. J Neurosci 2008; 28: 12788–12797.
80. Wang Y, Zhao Z, Chow N, et al. Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischaemic stroke in mice via protease activated receptor 1. Brain Res 2013; 1507: 97–104.
81. Guo H, Zhao Z, Yang Q, et al. An activated protein C analog stimulates neuronal production by human neural progenitor cells via a PAR1-PAR3-S1PR1-Akt pathway. J Neurosci 2013; 33: 6181–6190.
82. Maggio N, Itsekson Z, Ikenberg B, et al. The anticoagulant activated protein C (aPC) promotes metaplasticity in the hippocampus through an EPCRPAR1- S1P1 receptors dependent mechanism. Hippocampus 2014; Epub ahead of print.
83. O’Collins VE, Macleod MR, Donnan GA, et al. 1, 026 experimental treatments in acute stroke. Ann Neurol 2006; 59: 467–477.
84. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699–709.
85. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin Alfa (Activated) in Adults with Septic Shock. N Engl J Med 2012; 366: 2055–2064.
86. Bernard GR, Macias WL, Joyce DE, et al. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Crit Care 2003; 7: 155–163.
87. Bruckner M, Lasarzik I, Jahn-Eimermacher A, et al. High dose infusion of activated protein C (rhAPC) fails to improve neuronal damage and cognitive deficit after global cerebral ischaemia in rats. Neurosci Lett 2013; 551: 28–33.
88. Williams PD, Zlokovic BV, Griffin JH, et al. Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischaemic stroke. Curr Pharm Des 2012; 18: 4215–4222.
89. Lyden P, Levy H, Weymer S, et al. Phase 1 Safety, Tolerability and Pharmacokinetics of 3K3A-APC in Healthy Adult Volunteers. Curr Pharm Des 2013; 19: 7479–7485.
90. Mather T, Oganessyan V, Hof P, et al. The 2.8 Å crystal structure of Gla-domainless activated protein C. EMBO J 1996; 15: 6822–6831.